Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.41 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18171061 | 0.95 | TLR2 (0.46) | TLR2KMT2AMDM2TLR1 | |
| SCHEMBL31259028 | 0.95 | TLR2 (0.46) | TLR2KMT2AMDM2TLR1 | |
| SCHEMBL18171062 | 0.95 | TLR2 (0.46) | TLR2KMT2AMDM2TLR1 | |
| SCHEMBL16925663 | 0.89 | KMT2A (0.53) | TLR2KMT2AMDM2TLR1 | |
| SCHEMBL25728451 | 0.87 | MDM2 (0.44) | TLR2KMT2AMDM2TLR1 | |
| SCHEMBL14770862 | 0.86 | TLR2 (0.44) | TLR2KMT2AMDM2 | |
| SCHEMBL31010133 | 0.86 | KMT2A (0.52) | TLR2KMT2AMDM2TLR1 | |
| SCHEMBL20435349 | 0.86 | KMT2A (0.52) | TLR2KMT2AMDM2TLR1 | |
| SCHEMBL31493934 | 0.85 | TLR2 (0.51) | TLR2KMT2AMDM2TLR1 | |
| SCHEMBL5312217 | 0.85 | TLR2 (0.51) | TLR2KMT2AMDM2TLR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226313-A1 | CEACAM5 ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | SEAGEN INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226313-A1 | CEACAM5 ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | EPCAM, TOP2A, SPAG5 | TLR2 3918/4885KMT2A 1496/4885MDM2 4369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.